GTX (NASDAQ:GTXI) and Skinvisible (OTCMKTS:SKVI) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, profitability, earnings and risk.
This table compares GTX and Skinvisible’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
12.8% of GTX shares are owned by institutional investors. 40.9% of GTX shares are owned by insiders. Comparatively, 53.0% of Skinvisible shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Risk & Volatility
GTX has a beta of 2.54, suggesting that its share price is 154% more volatile than the S&P 500. Comparatively, Skinvisible has a beta of 1.51, suggesting that its share price is 51% more volatile than the S&P 500.
This is a breakdown of current recommendations and price targets for GTX and Skinvisible, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
GTX currently has a consensus target price of $31.00, indicating a potential upside of 3,037.65%. Given GTX’s higher possible upside, equities analysts plainly believe GTX is more favorable than Skinvisible.
Valuation & Earnings
This table compares GTX and Skinvisible’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
Skinvisible has higher revenue and earnings than GTX.
Skinvisible beats GTX on 6 of the 9 factors compared between the two stocks.
GTX Company Profile
GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of medicines for the treatment of stress urinary incontinence (SUI) and prostate cancer. It focuses on the development of selective androgen receptor modulators (SARMs) for the treatment of breast cancer, SUI, and Duchenne muscular dystrophy; and selective androgen receptor degraders to treat progressive castration-resistant prostate cancer. The company's lead SARM candidate is the enobosarm GTx-024, a Phase II open-label proof-of-concept clinical trial for patients with androgen receptor (AR) positive triple-negative breast cancer; and estrogen receptor positive and AR positive advanced breast cancer, as well as postmenopausal women with SUI. GTx, Inc. was founded in 1997 and is headquartered in Memphis, Tennessee.
Skinvisible Company Profile
Skinvisible, Inc., together with its subsidiaries, focuses on the development, manufacture, and sale of topical, transdermal, and mucosal polymer-based delivery system technologies and formulations for use in pharmaceutical, over-the-counter, personal skincare, and cosmetic markets. Its non-dermatological formulations offer solutions for women's health, pain management, and others markets. The company offers sunless tanning, anti-aging, and sunscreen products. Skinvisible, Inc. also licenses its products to manufacturers and marketers of brands internationally, as well as sells directly in the market; assists pharmaceutical clients in the early development of the formulations; and provides solutions to pharmaceutical companies by reformulating their products coming off patent with a new Invisicare patent, and new product benefits and line extensions. The company was formerly known as Microbial Solutions, Inc. and changed its name to Skinvisible, Inc. in February 1999. Skinvisible, Inc. was founded in 1998 and is based in Las Vegas, Nevada.
Receive News & Ratings for GTX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTX and related companies with MarketBeat.com's FREE daily email newsletter.